Announcement of the progress of the company's
committed items at the time when the stock was listed
on TWSE.
Date of events
2022/04/11
To which item it meets
paragraph 51
Statement
1.Date of occurrence of the event:2022/04/11
2.Company name:Tanvex BioPharma, Inc.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:
As requested by TWSE's letter No. 1061701748 issued on May 19,2017.
The Company issued the following undertakings when its stock was initial
listed:
(1)The disclosure in prospectuses for initial stock listing:
A. Brief account on research and development, manufacturing, sales
and main risk of biosimilar.
B. The difference of business model between Tanvex and other peers.
Analysis of competitive advantages and disadvantages.
C. Poject pipeline, current development progress, mass production
capabilities of each project, potencial failure risk of production
and the relative measures.
D. R&D investment, financial plan, potential risks of working capital
turnover and the relative measures.
E. The market competition situation and the strategy to face
first-mover advantages
F. The review and sales regulations of biosimilar in target market.
G. Patent/trade secret protection measures and potencial patent
litigation risk.
H. The basis and rationale for the setting of IPO price.
(2)The compamy has to report development progress in annual shareholders'
meeting to help shareholders understand the company's operating.
(3)Centralized custody is equired of the stocks about board directors,
major shareholders with over 5% of Tanvex's total outstanding shares,
CEO and R&D executives. One-half shares can be got back until one year
and turn a loss into pre-tax profit. The other one-half shares can be
obtained one year after the expiration date.
(4)The company should declare "Tanvex is a high-tech company that aims to
develop biosimillar and new drugs product." on the cover of prospectus.
Additionally, the company should remind investors that Tanvex are at the
loss condition and no revenue has been generated. The page number of
related risks should be printed on the cover of the prospectus.
6.Countermeasures:
The implementation status as of the first quarter of 2022 is as follows：
(1)Have been described in the Public disclosure for initial stock listing.
(2)Tanvex has reported development progress in 2021 annual shareholders'
meeting.
(3)Have completed the centralized custody of shares.
(4)Have printed relative information on the cover of the prospectus.
7.Any other matters that need to be specified:None.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Tanvex Biopharma Inc. published this content on 12 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 April 2022 01:10:06 UTC.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
TANVEX BIOPHARMA, INC. 
